Protagonist Therapeutics Inc — Quarterly Cash Flow (NASDAQ:PTGX) | MetaTrader

Open full chart

Financials

Overview Finanzbericht Statistics Dividends

Quarterly Annual

Total assets 603.86 M744.73 M742.13 M718.01 M701.69 M668.19 M Total liabilities 71.94 M69.43 M53.08 M49.99 M56.25 M53.48 M Total equity 531.91 M675.29 M689.05 M668.02 M645.44 M614.71 M Total liabilities & shareholders' equities 603.86 M744.73 M742.13 M718.01 M701.69 M668.19 M Total debt —————— Net debt ——————

Nachrichten

Protagonist Therapeutics earnings missed by $0.35, revenue fell short of estimates

Citizens raises Protagonist Therapeutics stock price target on drug approvals

Protagonist Therapeutics director Williams sells $1.48 million in shares

Protagonist Therapeutics: Direktor veräußert Aktien im Wert von 1,67 Mio. US-Dollar

Protagonist Therapeutics director sells $1.67 million in shares

Biotech-Ausblick 2026: Truist nennt seine Top-Aktien für die kommenden Jahre

Top Biotech Stocks to Watch in 2026, According to Truist

Protagonist Therapeutics: H.C. Wainwright erhöht Kursziel auf 117 US-Dollar

Protagonist Therapeutics stock price target raised to $117 from $80 at H.C. Wainwright

Protagonist Stock: Assessing The 2026 Upside For Icotrokinra And Rusfertide (PTGX)

Protagonist Therapeutics: CEO veräußert Aktien im Wert von 4 Mio. US-Dollar

Ali Asif, CFO of protagonist, sells $3.8m in PTGX stock